Trouble viewing this email?   Click Here                            Tue, April 21, 2009  
Informatics | Medicinal Chemistry | Biology | Clinical Pharmacology | Process R&D | Clinical Research
1

GVK Biosciences has developed a unique, one of its kind Online Structure Activity Relationship Database. GVK BIO plans to launch it at the Bio-IT World Conference & Expo 2009.

GOSTAR (GVK BIO Online Structure Activity Relationship) database is an online database where a user can Query, Browse, Retrieve and Export data into various formats. A user can register and subscribe online using PayPal.

The GOSTAR database contains compounds from Discovery and Development phase with SAR, ADME, Tox, Clinical, Preclinical and structural data (3.5 million inhibitors and 7 million quantitative SAR points).
3

Databases integrated in GOSTAR:

  • MedChem Database
  • Kinase Database
  • GPCR Database
  • Protease Database
  • Transporter Database
  • Phosphatase Database
  • Lipase Database
  • Phosphodiesterase
  • Drug Database
  • Clinical Candidate Database
  • Mechanism Based Toxicity Database

Database utilities:

  • Quick and easy access
  • Ease of maintenance, 24x7 online support
  • Unique structure with associated property data
  • Save and Refine query option
  • Can export entire data or data from selected fields
  • Regular Monthly updates
  • My Account" page to monitor own account
3
1

GVK Biosciences was appointed by DUPONT Crop Protection as a Strategic Alliance Partner for Discovery Chemistry Services in India. Both the companies have been working together for more than 5 years and DuPont said it was ready to advance to a new level of technical collaboration based on its valued relationship with GVK BIO.

GVK BIO has tackled projects that vary in degree of complexity in Crop Protection and has built a niche expertise to serve the Agro Science Community.

DuPontis a science-based products and services company. Founded in 1802, DuPont puts science to work by creating sustainable solutions essential to a better, safer, healthier life for people everywhere. Operating in more than 70 countries, DuPont offers a wide range of innovative products and services for markets including agriculture and food; building and construction; communications and transportation.
2
Manni Kantipudi & William Barnett, Director, DuPont Crop Protection on Partnership with GVK BIO.
3
1
1
Dr Shoibal Mukherjee
Senior Vice President
Clinical Development

Dr. Mukherjee comes to GVK BIO with extensive experience in managing global clinical trials. Prior to joining GVK BIO, Dr. Mukherjee served in Ranbaxy and Pfizer in senior positions.

Dr. Mukherjee graduated as a physician and is an MD and DM in Pharmacology. Professionally trained in clinical & pharmaceutical medicine, Dr. Mukherjee has vast experience in managing Clinical Trials, Medical Affairs, Clinical Data Management, and Clinical Pharmacology. Dr. Mukherjee has authored several research papers and is a visiting faculty for established universities and medical institutions. Dr. Mukherjee is the Founding President of the Indian Society for Clinical Research and a member of several committees.
3
Dr Rajesh Kher
Associate Director
Medical Writing

Dr. Kher held research and academic positions at the University of Chicago and the Indiana University School of Medicine between 1995 and 2007. He joined Eli Lilly & Co. in Indianapolis as a Drug Development Scientist and Senior Medical Writer. In this role he received a Spotlight Award from the company in recognition of his efforts and his leadership of the group. Dr.Kher comes to us from CREMA (Clinical Research Education and Management Academy), New Delhi, where he served as Principal and Head of the Delhi campus and gained valuable clinical research training and management experience. Dr .Kherhas been the co-author of a chapter in a book on Endocrinology, as well as written review articles and numerous scientific papers and abstracts.

4
Dr Vivek Ahuja
Director – Clinical Operations
CDM and Pharmacovigilance

An MBBS, MD and an MBA, Dr Ahuja is assisting GVK BIO set up its Pharmacovigilance team in addition to managing Clinical Operations. Dr. Ahuja earlier worked with Morepen Laboratories and Reliance Clinical . In his last assignment at Ranbaxy, Vivek was Section Head at the Medical Affairs and Clinical Research Department.

5
Dr William Harel
Vice President
Business Development

GVK BIO has also strengthened its international Clinical Research Business Development team by recruiting William Harel as Vice President – Business Development, in the West Coast of USA. A PhD in Immunology, William is responsible for developing the business of Clinical Research in the US and globally. William has over 20 years of experience in various companies including Chiron Corporation, AAI Pharma and Neeman Medical International.

GVK BIO inaugurates new
Clinical Research Facility at Gurgaon
GVK BIO opened a new 120 seater research facility at
Gurgaon, India in September 2008
GVK BIO's Clinical Pharmacology Unit approved by Ministry of Health, Turkey.
 
3
1
2

GVK Biosciences and Crelux set up Fragment based Drug Discovery Platform to deliver Lead Molecules

GVK Biosciences and Crelux have setup a highly robust fragment based drug discovery platform proven to deliver rapidly, viable lead molecules. CRELUX’s high performance structural biology technologies together with GVK BIO’s mature computer assisted drug design (CADD) tools and other components of its drug discovery & development engine, encompass all steps from challenging targets to novel drug candidates.

CRELUX and GVK BIO will provide seamless integration of all aspects of structure based drug design for the biopharmaceutical industry and furnishes accelerated timelines for moving molecules from concept into the clinic at an optimal cost. Fragment based Drug Design (FBDD) helps in visualizing binding modes and hence rationalizes an accelerated SAR allowing efficient lead optimization through CADD. CRELUX will leverage its capabilities of all aspects of multifaceted structural studies towards Xray elucidation of fragment or lead target complexes, whereas GVK BIO will perform all discovery chemistry and biology work including in silico, in vitro and in vivo studies as well as activities necessary to ensure preclinical candidate nomination.

GVK BIO forms Clinical Research alliance with Excel Pharma Studies

GVK BIO - Excel have decided to form an alliance to build on the strengths of each company and offer clients with services that span India and China.

The alliance provides clinical trial sponsors access to the scientific skills, talent pool, flexible resourcing, and cost-effectiveness of both India and China. India has sponsor friendly regulations and strength in Phase II/III clinical trials; China has strengths in its large market and post marketing Phase IV studies; Through the GVK BIO-Excel alliance sponsors will be able to conduct Phase II-IV trials using India and China as required with speed and efficiency.

Under the terms of the arrangement, GVK BIO and Excel will help sponsors conduct and manage Phase II-IV clinical trials, statistical analysis and medical writing. Any India trial for Excel will be carried out by the GVK BIO clinical research team and will be managed by a core project management team of Excel. Similarly, a GVK BIO China trial will be carried out by the Excel team and managed by GVK BIO’s project management team.

3
1
2
Dr.Tarun Khanna

Harvard Professor Tarun Khanna joins GVK BIO Board.

Harvard Professor Tarun Khanna joined the GVK BIO Board of Director. Dr.Tarun Khanna is the Jorge Paulo Lemann Professor at the Harvard Business School, where he has been a member of the Strategy group since 1993. He holds a BS degree from Princeton University and a Ph.D. from Harvard University. Dr.Khanna heads the Strategy course in the Harvard MBA program and the Strategy, Leadership & Governance Executive Education program. He also lectures and consults with companies and governments worldwide. Dr.Khanna has contributed articles to Harvard Business Review and Foreign Policy and has served as an expert for major news organizations such as Wall Street Journal, The Economist, the Far Eastern Economic Review, CNN, and CNBC.

Serving on the Advisory Boards of several multinational and emerging market companies in the financial services, automotive, life sciences and agribusiness sectors, Dr. Khanna has experience in a wide variety of industries. He was nominated a Young Global Leader by the World Economic Forum in 2007.

Dr. Tarun Khanna’s vast experience in global strategy and understanding of the emerging markets is an added strength to GVK BIO.

3
1
Annual Data/EDC Meeting Orlando, FL April 27 -29, 2009
Bio-IT World Conference & Expo 2009 Boston, MA April 27-29, 2009
Annual Meeting of CRO Partnerships Orlando, FL April 28-30, 2009
AIPLA meeting San Diego, CA May 13-15, 2009
ATS San Diego May 15-20, 2009
The Burrill India Life Sciences Meeting Atlanda, GA May 16, 2009
BIO2009 Atlanta May 18-21, 2009
PIUG 2009 TX, USA May 2-7, 2009
Biomarker World Congress Philadelphia, PA May 27-29, 2009
ASCO 2009 Orlando, FL May 29 - 2 June, 2009
Protein Kinase Targets Cambridge, MA June 1-3, 2009
AAPS Workshop on The 21st Century Bioanalytical Laboratory: Maximizing Quality and Efficiency through Innovation Washington State Convention and
Trade Center, Seattle, WA, USA		 June 20-21, 2009
The 45th DIA Annual Meeting San Diego Convention Center,
San Diego, USA		 June 21-25, 2009
Pharma Outsourcing London June 25, 2009
15 EGA Annual Conference Barcelona June 3-5, 2009
Structure-Based Drug Design Cambridge, MA June 4-5, 2009
World Pharma Congress Philadelphia June 9-11, 2009
3
   Career Opportunities  @  GVK BIO

You are receiving this e-mail because you are either
a registered member or requested for a newsletter from gvkbio.com

Click here to Subscribe or Unsubscribe

For Questions or assistance, please contact: corpcomm@gvkbio.com

Copyright@2009. GVKBIO Ltd. All rights reserved.